High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C) is the main therapeutic target in the treatment of hypercholesterolemia. Small interfering RNA (siRNA) inclisiran is a new drug, which targets PCSK9 mRNA in the liver, reducing concentrations of circulating LDL-C. In randomized trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Makhmudova, U., Schatz, U., Perakakis, N., Kassner, U., Schumann, F., Axthelm, C., Stürzebecher, P., Sinning, D. L., Doevelaar, A., Rohn, B., Westhoff, T., Vogt, A., Scholl, M., Kästner, U., Geiling, J.-A., Stach, K., Mensch, J., Lorenz, E., Paitazoglou, C., Eitel, I., Baessler, A., Steinhagen-Thiessen, E., Koenig, W., Schulze, P. C., Landmesser, U., Laufs, U., Weingärtner, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584696/
https://www.ncbi.nlm.nih.gov/pubmed/37422840
http://dx.doi.org/10.1007/s00392-023-02247-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584696/
https://www.ncbi.nlm.nih.gov/pubmed/37422840
http://dx.doi.org/10.1007/s00392-023-02247-8

Ejemplares similares